VERACYTE INC (VCYT) Stock News
NASDAQ:VCYT - Nasdaq - US92337F1075 - Common Stock - Currency: USD
VCYT Latest News, Press Relases and Analysis
Investors seeking growth at a reasonable cost should explore VERACYTE INC (NASDAQ:VCYT).
NASDAQ:VCYT is scoring great on several growth aspects while it also shows decent health and profitability. At the same time it remains remains attractively priced.
Veracyte to Participate in Upcoming Investor Conferences
Veracyte Stock Surges 30.9% in a Year: What's Driving the Rally?
Strength in VCYT's Afirma and Decipher tests continues to draw investors' attention.
Why Recursion Pharmaceuticals Stock Plummeted 24% This Week
The results of a recent survey released Tuesday showed President Trump's actions are likely to make it harder for biotech companies like Recursion to raise capital. Shares of Recursion Pharmaceuticals (NASDAQ: RXRX) fell this week. Recursion revealed disappointing first-quarter earnings on Monday and announced it would pare down its development pipeline.
Veracyte Stock Gains on Q1 Earnings and Revenue Beat, Gross Margin Up
VCYT registers robust growth from its market-leading Decipher Prostate and Afirma tests in the first quarter of 2025.
Should I Take Money Out of My Roth IRA To Pay My Debt? Experts Weigh In
High-interest debt can feel like a dead weight. While it may be tempting to pull money out of a Roth IRA to pay off debt, is it a good idea?
Mentions: FIS
What Makes Veracyte (VCYT) a New Buy Stock
Veracyte (VCYT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Veracyte (VCYT) Q1 Earnings and Revenues Beat Estimates
Veracyte (VCYT) delivered earnings and revenue surprises of 55% and 3.17%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: TMCI
Veracyte Announces First Quarter 2025 Financial Results
Ekso Bionics (EKSO) Reports Q1 Loss, Misses Revenue Estimates
Ekso Bionics (EKSO) delivered earnings and revenue surprises of -9.09% and 28.95%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: EKSO
SAP, buoyed by cloud shift, extends CEO, CFO contracts
CEO Christian Klein will remain at the helm through 2030 as the push to migrate customers from on-premises ERP systems continues, the company said Monday.
Veracyte Announces Expanded Availability of Decipher Prostate Test to Patients with Metastatic Prostate Cancer
The Blood Test Revolution: It's A New Day In Cancer. Guardant, Natera And Exact Are Here For It.
A revolution in oncology could help cancer survivors in the U.S. and bolster Guardant Health, Natera and Exact Sciences.
Should You Continue to Hold Veracyte Stock in Your Portfolio?
Strength in the Afirma and Decipher franchises continues to bode well for VCYT stock.
Veracyte to Release First Quarter 2025 Financial Results on May 7, 2025
Is Argenx SE (ARGX) the Best Growth Stock to Buy According to Billionaires?
We recently published a list of 10 Best Growth Stocks to Buy According to Billionaires. In this article, we are going to take a look at where Argenx SE (NASDAQ:ARGX) stands against other best growth stocks to buy according to billionaires. Can the Stock Market Have a Big Rebound? The stock market has been on […]
International Growth Drives GMED Stock Amid Fierce Competition
Globus Medical is gearing up for a series of product launches throughout the Musculoskeletal portfolio in the coming months of 2025.
Here's Why Veracyte (VCYT) is a Strong Growth Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Is Essex Property Trust (ESS) The Most Expensive Stock Insiders Are Dumping In March?
We recently published a list of 20 Most Expensive Stocks Insiders Are Dumping In March. In this article, we are going to take a look at where Essex Property Trust, Inc. (NYSE:ESS) stands against other most expensive stocks insiders are dumping in March. After being in the green for a few trading sessions, the broader […]
Veracyte (VCYT) Introduces AI-Powered Cancer Detection – Faster and More Accurate Than Ever!
We recently published a list of 9 AI News and Ratings on Investors’ Radar. In this article, we are going to take a look at where Veracyte, Inc. (NASDAQ:VCYT) stands against other AI news and ratings on investors’ radar. According to a Reuters report posted on March 25, Chinese AI firms have made significant progress […]
Qualcomm (QCOM) Fights Back Against Arm’s Tech Restrictions – What It Means for the Chip Industry
We recently published a list of 9 AI News and Ratings on Investors’ Radar. In this article, we are going to take a look at where QUALCOMM Incorporated (NASDAQ:QCOM) stands against other AI news and ratings on investors’ radar. According to a Reuters report posted on March 25, Chinese AI firms have made significant progress […]
Viemed Healthcare, Inc. (VMD): A Bull Case Theory
We came across a bullish thesis on Viemed Healthcare, Inc. (VMD) on Substack by Petty Cash. In this article, we will summarize the bulls’ thesis on VMD. Viemed Healthcare, Inc. (VMD)’s share was trading at $7.25 as of March 27th. VMD’s trailing P/E was 25.89 according to Yahoo Finance. Viemed Healthcare (VMD) reported solid quarterly results, surpassing […]
Is Quest Diagnostics Stock Worth Holding Onto Right Now?
Strong momentum in Advanced Diagnostics and strategic acquisitions continues to attract investors to DGX.
National Vision Stock Rises 28.2% YTD: Will the Rally Continue?
EYE's strength in its largest brand and actions to achieve a healthier store fleet position the stock favorably.
